ERCC1新抗体在非小细胞肺癌铂类用药分子诊断中的应用

Application of new ERCC1 antibody for molecular diagnosis of platinum chemotherapy in nonsmall cell lung cancer

背景与目的:DNA切除修复交叉互补基因1(excision repair cross complementation group l,ERCC1)的高表达与铂类药物的耐药性相关。以往研究中常采用ERCC1抗体8F1,近来发现其有非特异性。为了检测ERCC1新抗体4F9在非小细胞肺癌(non-small cell lung cancer,NSCLC)铂类用药的指导作用。方法:采用免疫组化法对72例NSCLC患者肿瘤组织进行ERCC1检测,分析患者的ERCC1蛋白表达与临床特征、铂类为基础化疗方案的疗效及患者生存期的关系。结果:72例NSCLC组织中ERCC1蛋白高表达者占55.5%。ERCC1的蛋白表达与患者的性别、年龄、组织学类型、临床分期、淋巴结转移均无明显相关性(P>0.05);ERCC1低表达患者的化疗有效率、中位生存期及2年生存率均高于高表达患者(62.5%vs 37.5%;22.9 vs 18.4个月;46.9%vs 37.5%),差异均有统计学意义(P<0.05)。结论:ERCC1新抗体4F9免疫组化法检测ERCCl的表达有助于筛选NSCLC患者辅助化疗方案,指导患者术后铂类药物的个体化治疗。

Background and purpose： High expression of excision repair cross-complementing 1 （ERCC1） is related to resistance in patients treated with platinum-containing regimens. The ERCCI antibody 8F1 was usually used in past studies, but it was found to have no-specificity recently. This study aimed to investigate the predictive role of a new ERCC1 antibody 4F9 to platinum chemotherapy in non-small cell lung cancer （NSCLC） patients. Methods： Expression of ERCC1 was detected using antibody 4F9 by immunohistochemistry （IHC） in 72 NSCLC tissues. The relationship between the expression of ERCC1 and the clinical pathological parameters, the efficacy of platinum chemotherapy and overall survival of patients were explored by statistical analysis. Results： The high expression of ERCC1 protein was 55.5%in 72 cases. There was no significant correlation between the ERCC1 expression with gender, age, pathological type, clinical stage and lymphatic metastasis （P〉0.05）. Patients with low expression of ERCC1 had significantly higher response rates to platinum chemotherapy, longer median survival time and 2-years survival rate comparing with those with high expression of ERCC1 （62.5% vs 37.5%; 22.9 vs 18.4 month; 46.9% vs 37.5%）, respectively （P〈0.05）. Conclusion： The expression analysis of ERCCI using new ERCC1 antibody 4F9 by IHC method is helpful to assign chemotherapeutic regimen, and guide individual platinum chemotherapy for post-operation patients.